A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, controlled, real world study. Patients will be
randomly enrolled into the test group and the control group at a ratio of 1:1 during the
screening period. The test group will choose to add Agomepratin on the basis of a
second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc., see Annex
A), and the control group will either use a second-generation antipsychotic drug (olanzapine,
aripiprazole, risperidone, etc.) for 24 consecutive weeks, To explore the efficacy and safety
of the second generation antipsychotic drugs combined with agomeratine regimen in the real
world for negative symptoms of schizophrenic patients. Group sequential design is used as the
method of interim analysis in the research process. If the research purpose is reached in
advance, the research can be terminated. The study followed GRACE standards.